(Q42967337)

11 November 2017

title

Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU). (English)

1 reference

11 November 2017

1 reference

1 reference

Barbara K Burton

1

1 reference

11 November 2017

Heather Bausell

2

1 reference

11 November 2017

Rachel Katz

3

1 reference

11 November 2017

Holly Laduca

4

1 reference

11 November 2017

Christine Sullivan

5

1 reference

11 November 2017

publication date

27 June 2010

1 reference

Molecular Genetics and Metabolism

11 November 2017

published in

1 reference

11 November 2017

volume

101

1 reference

11 November 2017

issue

2-3

1 reference

11 November 2017

page(s)

110-114

1 reference

Executive function in early-treated phenylketonuria: profile and underlying mechanisms.

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.06.015

Psychiatric symptoms and disorders in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.06.015

Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.06.015

Stability of blood phenylalanine levels and IQ in children with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.06.015

Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.06.015

Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.06.015

Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.06.015

Pahenu1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.06.015

Paired comparisons between early treated PKU children and their matched sibling controls on intelligence and school achievement test results at eight years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.06.015

ADHD, learning, and academic performance in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.06.015

How practical are recommendations for dietary control in phenylketonuria?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.06.015

10.1016/J.YMGME.2010.06.015

7 January 2021

Identifiers

DOI

1 reference

11 November 2017

1 reference